Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Yo-Yo Dieting May Significantly Increase Kidney Disease Risk in People With Type 1 Diabetes Feb. 4, 2025 — Body-weight cycling (also known as yo-yo dieting) has been shown to significantly ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression to chronic kidney disease ...

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...